Over the forecast period, digestive remedies is projected to see retail value (constant 2024 prices) growth. In retail volume terms, all significant categories are set to see retail volume increases through or at least in the second half of the forecast period.
Towards the end of the review period, INVIMA switched mebeverine in 135mg concentration from prescription to OTC, allowing brands like Duspatalin (Laboratorio Franco Colombiano Lafrancol) to be advertised for IBS treatments. Nevertheless, the impact on the market size of IBS treatments has been dampened.
In Colombia, OTC digestive enzymes are negligible. However, in late 2023, INVIMA included lactase on the OTC list.
Delivery:
Files are delivered directly into your account soon after payment is received and any tax is certification is verified (where applicable).
This report comes in PDF with additional info in Excel included.
Understand the latest market trends and future growth opportunities for the Digestive Remedies industry in Colombia with research from Euromonitor International's team of in-country analysts – experts by industry and geographic specialisation.
Key trends are clearly and succinctly summarised alongside the most current research data available. Understand and assess competitive threats and plan corporate strategy with our qualitative analysis, insight and confident growth projections.
If you're in the Digestive Remedies industry in Colombia, our research will help you to make informed, intelligent decisions; to recognise and profit from opportunity, or to offer resilience amidst market uncertainty.
Digestive Remedies
Includes remedies designed and marketed to treat gastrointestinal problems.
See All of Our DefinitionsThis report originates from Passport, our Digestive Remedies research and analysis database.
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extraction Free!